Drugs / GTAEXS617
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07633756 | Oct 2026 → Dec 2029 expected | leiomyosarcoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05985655 | Jul 2023 → Jan 2028 expected | head and neck squamous cell carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma +2 | Exscientia AI Limited | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GTAEXS617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05985655 ↗ |
| Known as | REC-617 | “A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy” NCT07633756 ↗ |
| Action | Inhibit | “Selective CDK7 Inhibitor” NCT07633756 ↗ |
| Route | Oral | “Participants will receive GTAEXS617 oral tablets in increasing doses.” NCT05985655 ↗ |
| Target | CDK7 | “Selective CDK7 Inhibitor” NCT07633756 ↗ |